Lusacomfar alfa

芦沙补体因子α

Report date: 2023/03/17 14:21:52

Base Information

Drug NameLusacomfar alfa
Drug Alias NamerCFHRecombinant complement factor HGEM-103
ClassificationBiologics > Protein drugs > Recombinant protein
Mechanisms of ActionComplement factor H replacements
TargetsComplement factor H
Therapy Area/IndicationsGeographic AtrophyMacular DegenerationRetinal Diseases +[4
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesGemini Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesGemini Therapeutics Inc
Active IndicationsN/A
Inactive IndicationsGeographic AtrophyMacular DegenerationRetinal Diseases +[4

Other Information

ATC CodeN/A
Related LinksN/A